How to Get Started Sample Clauses

How to Get Started. 3 Application for Regular, Rollover and Xxxx IRAs, SEPs, and SAR-SEPs.......................................... 5 XXX Transfer, Direct Rollover & Conversion Form............................ 7 Authorization to Add or Convert to a Xxxx XXX or Other XXX................. 9
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
How to Get Started. This Price Agreement incorporates a Master Agreement and Participation Agreement. Each participating member must negotiate and sign a Participation Agreement with an eligible vendor to participate in this program. Two versions of the Participation Agreement exist: (1) Models A, B, C with ComDoc and (2) Model D with each eligible vendor. Participating members have the opportunity to review the IUC-PG Master Agreements, but cannot alter them. Participation Agreements may be negotiated and altered with the eligible vendor(s). Member institutions may contact the IUC-PG for copies of the Master Agreement and draft Participation Agreement. Please direct any questions on these Master Agreements to Xxxxxxxx Xxxxx-Xxxxxxx, Executive Director of IUC-PG (xxxxx-xxxxxxx.0@xxx.xxx). Please contact the following vendors with questions or begin negotiating your Participation Agreement: Models A, B and C: ComDoc, A Xerox Company Xxxxxx Xxxx, Xx. Vice President Phone: (000) 000-0000 Cell: (000) 000-0000 Email: XXxxx@xxxxxx.xxx Model D: Xxxxxxxxx XxXxxxxx Enterprises Xxxxxx X. Xxxxxxx, Strategic Accounts Manager 00000 Xxxxxxxxx Xx., Xxxxxxxxxx, Xxxx 00000 Phone: (000) 000-0000 xxx 0000 Cell: (000) 000-0000 Email: x.xxxxxxx@xxxxxxxxxxxxxxxxx.xxx Millennium Business Systems Xxxxx X. Xxxxxxx 00000 Xxxxxxxxxx Xxxx, Cincinnati, OH 45249 Phone: 000-000-0000 Cell: 000-000-0000 Email: xxxxxxxx@xxxxxxxxxxxxx.xxx Modern Office Methods Xxxxxxx Xxxxxxx 0000 Xxxx Xxxxxx Xxxxx, Xxxxx 000, Xxxx Xxx, XX 00000 Phone: (000) 000-0000 Email: xxxxxxx.xxxxxxx@xxxxxx.xxx ADDITIONAL DETAILS Please contact xxxx@xxxxx.xxx with any questions.
Sample 1
How to Get Started. Establishing a legacy agreement at the Community Foundation is straightforward and easy. Our staff will prepare a customized draft agreement for you to review. We encourage you to consider the agreement as a part of your estate planning and review with your advisors. Once established, the Foundation will ensure your charitable intent is met when a gift is made from your will or estate. MINIMUMS AND FEES: There is no miniumum needed to establish a legacy agreement. However, the minimum balance to open and make distributions for the specified fund outlined in your aggrement must be met with the establising gift from your will or estate. There is also no fee to establish a legacy agreement. Once the establishing gift is made and the specified fund is created, it will be assessed administrative and investment management fees based on the fund type. 000 X Xxxxxxxx Xx, Xxxxx 000, Xxxxxxxxxx, XX 00000
Sample 1
How to Get Started. Please complete the form below and fax it to 0-000-000-0000. Following that, our representative will contact you directly to discuss how the Authority can facilitate your collection activities and help you with the required registration process with Ecology and answer your questions. Collector Participation Form Name of Collector Organization/Company: EPR Number (assigned by Ecology to registered collectors): You may register with the Department of Ecology at: xxxx://xxx.xxx.xx.xxx/programs/swfa/eproductrecycle/collector.html Collection Site Name: Ecology requires that all participating collection sites provide staffed hours of operation and utilize enclosed storage. For each location that might participate in the Authority’s collection system, please provide the following information. Location: Do you plan to collect all covered electronic products at this site? Yes / No (TVs, monitors, desktops, laptops) If no, specify which will be collected: This site may be able to receive larger quantities from charities, school districts, small businesses and small governments in my area. Yes / No Current or Planned Days/Hours of Operation: Contact Name: Contact Phone Number: Contact Email Address: I am authorized by my organization to pursue participation in the Washington Materials Management and Financing Authority’s Standard Plan approved July 17th, 2009. I agree to work with Authority representatives to develop a mutually agreeable arrangement to receive or collect used covered electronic products at the site listed above. Print Name Signature Title Phone Number/Email Date
Sample 1

Related to How to Get Started

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Manufacture 2.1. The LED(s) on the LED module shall be equipped with suitable fixation elements.

  • Inventions Retained and Licensed I have attached hereto, as Exhibit A, a list describing all inventions, original works of authorship, developments, improvements, and trade secrets which were made by me prior to my employment with the Company (collectively referred to as “Prior Inventions”), which belong to me, which relate to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, I represent that there are no such Prior Inventions. If in the course of my employment with the Company, I incorporate into a Company product, process or machine a Prior Invention owned by me or in which I have an interest, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or machine.

  • Manufacturing Services Jabil will manufacture the Product in accordance with the Specifications and any applicable Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***].

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • Engineering Services Definition: Engineering Services includes any service or creative work, the adequate performance of which requires education, training and experience in the application of special knowledge in consulting, investigating, evaluating, planning and designing, engineering principles. Engineering Services covered by the Xxxxxx Architect-Engineers Act (40 U.S.C. 1102) are not covered in the primary scope of OASIS SB. Examples: Service areas that are included under the Engineering Services discipline include, but are not limited to the following:

  • Research Records Each Party shall maintain records of each Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Program. All laboratory notebooks shall be maintained for no less than the term of any Patent issuing therefrom. All other records shall be maintained by each Party during the relevant Research Term and for [**] thereafter. All such records of a Party shall be considered such Party’s Confidential Information.

Time is Money Join Law Insider Premium to draft better contracts faster.